- This event has passed.
Open to the Oxford Entrepreneurship Network hosted by OEN-UK. (All Oxford University students and alumni are welcome.)
Three-Part Format: (1) Keynote(2) Founder Pitch (3) Q&A (4) Virtual Networking (Round Robin)
Keynote: Entrepreneurship from Academic Research
20 minute talk
Professor Hagan Bayley is the Professor of Chemical Biology at the University of Oxford, and his research has produced two spinout companies, Oxford Nanopore and OxSyBio. He has studied and worked at Harvard and MIT, coming back to Oxford in 2003.
Founder Pitch: Nucleome Therapeutics
10 minute pitch
Speaker: Dr Danuta Jeziorska
Dr. Danuta Jeziorska is a Co-founder and CEO of Nucleome Therapeutics and also an Honorary Senior Scientist at the University of Oxford.
Previously, she co-founded Innovation Forum Oxford, for which she was recognised as one of the Movers and Shakers in BioBusiness in 2018. Her scientific expertise lies in decrypting how genes are regulated, a field which she has been working on over the last 12years.
Prior to co-founding both Nucleome and Innovation Forum Oxford, Danuta was a Senior Postdoctoral Research Scientist, working under the guidance of Prof Doug Higgs in the Gene Regulation Laboratory, at the MRC Molecular Haematology Unit at the MRC Weatherall Institute of Molecular Medicine, University of Oxford; where research focused on decoding how genes are regulated.
Before moving to Oxford, Danuta completed a PhD in Systems Biology from the University of Warwick and obtained a BSc degree in Biotechnology from the University of Silesia in Poland.
Nucleome Therapeutics is a fast-growing biotech start-up that is unlocking the non-coding genome for drug target discovery and development. It spun out from the University of Oxford in2019 after a decade of foundational research, with seed investment of £5.2mfrom Oxford Sciences Innovation. Their proprietary platform combines machine learning and novel molecular biology techniques that define the 3D structure of the genome and enables variant functional validation at scale, giving them dramatically enhanced understanding of how genetic variation drives disease to discover new drug targets guided by genetics for internal development and partnering. The company’s initial focus is on autoimmune diseases.
Followed by 20minutes Q&A for both speakers
Virtual Networking(Round Robin)
We will devote up to 20 minutes to our Round Robin, where each participant who wishes to do so will be given 30to 45 seconds to introduce themselves by: discussing their professional background and specifically stating a request (if any) for a way the group could help them. This part of the event is limited to 45 participants.
OEN members participating in the Round Robin will be asked to keep their cameras on so the host knows they want to participate in virtual networking.
Natalya Vilyavina https://www.linkedin.com/in/vilyavina/
Aran Bates https://www.linkedin.com/in/aran-bates/